Leukapheresis Market Share

North American Market Forecast

North American leukapheresis market is poised to hold the largest share of 36% during the forecast period. The primary drivers of the current leukapheresis industry are an increase in neurological illnesses and blood-related disorders like "leukemia," which are already extremely frequent and common in this region. Additionally, the region is home to highly qualified medical personnel and well-equipped facilities. Furthermore, the region sets the standard for the use of cell-based treatments including stem cells and CAR T-cell therapy. For instance, in December 2021, T-ChargeTM, Novartis's next-generation CAR-T platform, was unveiled. It will act as the basis for several novel investigational CAR-T cell therapies that the company has in the works. The leukapheresis market expanded as a result of the region's increasing need for cell-based therapies.

European Market Statistics

Leukapheresis market in Europe is expected to grow with a share of 28% by the end of 2036. The rising incidence of blood disorders is one of the key factors expanding the market in the region. Also, the growth can be attributed to the growing investment in the healthcare sector. For instance, 2018 saw USD 1.95 billion financed by Europe in research and innovation through 1.708 initiatives in 20 Member States. The top three countries with the largest financing shares are Spain, Hungary, and Poland. Furthermore, Europe is a center for immunotherapy, cancer, and hematology clinical research and innovation. Leading academic institutions and pharmaceutical businesses are present, which promotes innovation and expands the leukapheresis market.